At least 100 illegal miners have died while trapped in a South African mine, group says
Reckless driver damages Mt. Murphy Bridge, prompting extended closure
Multiple officers hospitalized after responding to illegal car meetup
Roki Sasaki won't sign with New York Yankees, AP source says
Ryanair calls for alcoholic drink limit at EU airports amid legal action against unruly passenger
Company linked to Alex Jones doubles offer to buy Infowars after failed bankruptcy auction
Elon Musk says a third patient got a Neuralink brain implant. The work is part of a booming field
IRS is sending out automatic stimulus payments. Who is getting them?
Lasers help archaeologists study ancient tattoos on Peruvian mummies
(Reuters) - Bristol Myers Squibb has acquired Orum Therapeutics' experimental therapy to treat a type of blood cancer for a total value of up to $180 million, the privately held company said on Monday.
The therapy, ORM-6151, which helps degrade a specific protein hard to treat previously, has received the U.S. Food and Drug Administration's (FDA) clearance for an early stage study.
The deal includes an upfront payment of $100 million and milestone payments, Orum said, without disclosing further details.
(Reporting by Khushi Mandowara in Bengaluru; Editing by Dhanya Ann Thoppil and Sriraj Kalluvila)
